ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
Accounts Receivables
ADC Therapeutics SA
Accounts Receivables Peer Comparison
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADC Therapeutics SA
NYSE:ADCT
|
Accounts Receivables
$25.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
163%
|
CAGR 10-Years
N/A
|
|
AC Immune SA
NASDAQ:ACIU
|
Accounts Receivables
CHf15m
|
CAGR 3-Years
111%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Accounts Receivables
$200m
|
CAGR 3-Years
1 160%
|
CAGR 5-Years
357%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Accounts Receivables
CHf27.9m
|
CAGR 3-Years
47%
|
CAGR 5-Years
49%
|
CAGR 10-Years
22%
|
|
Idorsia Ltd
SIX:IDIA
|
Accounts Receivables
CHf4.3m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
SIX:KURN
|
Accounts Receivables
CHf6.4m
|
CAGR 3-Years
84%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Accounts Receivables?
Accounts Receivables
25.2m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Accounts Receivables amounts to 25.2m USD.
What is ADC Therapeutics SA's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
163%
Over the last year, the Accounts Receivables growth was -66%.